Leiden mutation (rs6025) in a severe COVID-19 pneumonia patient with Down syndrome: a clinical case

V.I.  Pokhylko; Y.I.  Cherniavska; L.Y.  Fishchuk; Z.I.  Rossokha; O.G.  Ievseienkova; O.M.  Dubitska; O.F.  Popova; M.М.  Fastovets; O.О.  Kaliuzhka; N.G.  Gorovenko

doi:10.26641/2307-0404.2023.4.294283

Authors

V.I. Pokhylko Poltava State Medical University, Shevchenko str, 23, Poltava, Ukraine https://orcid.org/0000-0002-1848-0490
Y.I. Cherniavska Poltava State Medical University, Shevchenko str, 23, Poltava, Ukraine https://orcid.org/0000-0002-4522-7538
L.Y. Fishchuk SI “Reference-center for Molecular Diagnostic of Public Health Ministry of Ukraine”, Dorohozhytska str., 9, Kyiv, 04112, Ukraine https://orcid.org/0000-0001-9999-7389
Z.I. Rossokha SI “Reference-center for Molecular Diagnostic of Public Health Ministry of Ukraine”, Dorohozhytska str., 9, Kyiv, 04112, Ukraine https://orcid.org/0000-0002-4767-7364
O.G. Ievseienkova Shupyk National University of Healthcare of Ukraine, Dorohozhytska str., 9, Kyiv, 04112, Ukraine https://orcid.org/0000-0001-9315-6108
O.M. Dubitska SI “Reference-center for Molecular Diagnostic of Public Health Ministry of Ukraine”, Dorohozhytska str., 9, Kyiv, 04112, Ukraine https://orcid.org/0000-0002-2400-4589
O.F. Popova SI “Reference-center for Molecular Diagnostic of Public Health Ministry of Ukraine”, Dorohozhytska str., 9, Kyiv, 04112, Ukraine https://orcid.org/0000-0002-8298-858X
M.М. Fastovets Poltava State Medical University, Shevchenko str, 23, Poltava, Ukraine https://orcid.org/0000-0003-4843-496X
O.О. Kaliuzhka Poltava State Medical University, Shevchenko str, 23, Poltava, Ukraine https://orcid.org/0000-0003-4385-4244
N.G. Gorovenko Shupyk National University of Healthcare of Ukraine, Dorohozhytska str., 9, Kyiv, 04112, Ukraine https://orcid.org/0000-0003-4227-7166

DOI:

https://doi.org/10.26641/2307-0404.2023.4.294283

Keywords:

clinical case, COVID-19, Down syndrome, pneumonia, Leiden mutation, rs6025

Abstract

COVID-19 was first reported in December 2019 in Wuhan (Hubei Province, China). Later, the pandemic of this disease took the world by storm, challenging the medical community. Its clinical manifestations vary from asymptomatic to a severe course that requires hospitalization and intensive therapy with oxygen support. The mortality rate in patients with a severe course of COVID-19 can exceed 50% The majority of fatal cases of COVID-19 were associated with thrombotic events, despite the prophylactic use of anticoagulant therapy. Numerous theoretical overviews and research articles indicate the need for genetic testing in patients with COVID-19 to determine the genetic profile of proteins involved in thrombophilia. According to the researchers, the Leiden mutation (G1691A, rs6025) of the FV gene is one of the promising candidates for testing. The aim of the work was to demonstrate the clinical features of the severe course of COVID-19 in the presence of the Leiden mutation. 58 patients with COVID-19 of the intensive care unit were genotyped. The Leiden mutation in the heterozygous state was found only in one patient, who had Down syndrome. The Leiden mutation was detected with a frequency of 1.72% in the investigated group. The described clinical case clearly showed that individuals with Down syndrome, associated with hereditary thrombophilia are at risk of undesirable clinical consequences in the treatment of COVID-19. The condition of the patient with the Leiden mutation was severe when admitted to the hospital. The score according to the sequential organ failure assessment scale was 2 points. Bilateral multisegmental pneumonia was detected on the X-ray. On the second day after admission, due to the development of acute respiratory distress syndrome and multiple organ failure, the patient was transferred to the intensive care unit, where he received oxygen therapy through a facial mask. Medical treatment was carried out according to the protocol: non-steroidal anti-inflammatory drugs, antibacterial therapy, anticoagulants, sympatho¬mimetics, and glucocorticosteroids. Despite the medical measures taken, progression of respiratory failure, renal failure, and portal hypertension was noted. On the 11th day, the patient developed asystole. Resuscitation measures were unsuccessful. Thus, the described case of a severe course of COVID-19 in a carrier of a heterozygous variant of the Leiden mutation with Down syndrome confirms the recommendations regarding the need for genetic testing for thrombophilia in high-risk groups and the appointment of personalized measures to prevent complications.

References

Mainous AG, Rooks BJ, Wu V, Orlando FA. COVID-19 post-acute sequelae among adults: 12 month mortality risk. Front Med (Lausanne). 2021;8:778434. doi: https://doi.org/10.3389/fmed.2021.778434

Parra-Medina R, Herrera S, Mejia J. Systematic review of microthrombi in COVID-19 autopsies. Acta Haematol. 2021;144(5):476-83. doi: https://doi.org/10.1159/000515104

Burlacu A, Genovesi S, Popa IV, Crisan-Dabija R. Unpuzzling COVID-19 prothrombotic state: are preexis-ting thrombophilic risk profiles responsible for heterogenous thrombotic events? Clin Appl Thromb Hemost. 2020;26:1-5. doi: https://doi.org/10.1177/1076029620952884

Kiraz A, Sezer O, Alemdar A, Canbek S, Du-man N, Bisgin A, et al. Contribution of genotypes in Prothrombin and Factor V Leiden to COVID-19 and di-sease severity in patients at high risk for hereditary thrombophilia. J Med Virol. 2023;95(2):e28457. doi: https://doi.org/10.1002/jmv.28457

Izmailova O, Shlykova O, Vatsenko A, Iva-shchen¬ko D, Dudchenko M, Koval T, et al. Allele С (rs5186) of AT1R is associated with the severity of COVID-19 in the Ukrainian population. Infect Genet Evol. 2022;98:1-7. doi: https://doi.org/10.1016/j.meegid.2022.105227

Fiore JR, Ciarallo M, Di Stefano M, Sica S, Sca-rale M, D'Errico M, et al. Severe systemic thrombosis in a young COVID-19 patient with a rare homozygous prothro¬mbin G20210A mutation. Infez Med. 2021;29(2):259-62.

Stevens H, Canovas R, Tran H, Peter K, McFa-dyen JD. Inherited thrombophilias are associated with a higher risk of COVID-19-associated venous thrombo-embolism: a prospective population-based cohort study. Circulation. 2022;145(12):940-2. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.057394

Lapić I, Radić Antolic M, Horvat I, Remužić V, Palić J, Rogić D, et al. Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: A pilot study. J Med Virol. 2022;94(8):3669-75. doi: https://doi.org/10.1002/jmv.27774

Kaminskyi VV, Vorobei LI, Zhdanovych OI, Kor-niienko SM, Kolomiichenko TV, Fastovets ОР. [Clinical and genetic determinants of severe course of COVID-19 in pregnant women]. Reprod endocrinol. 2022;3(65):38-43. Ukrainian.

doi: https://doi.org/10.18370/2309-4117.2022.65.38-43

Damar İH, Recep E, Kiliçaslan Ö. Frequency of hereditary prothrombotic risk factors in patients with Down syndrome. Konuralp Med J. 2021;13(1):89-93. doi: https://doi.org/10.18521/ktd.8239000

Turki RF, Assidi M, Banni HA, Zahed HA, Karim S, Schulten HJ, et al. Associations of recurrent mis-carriages with chromosomal abnormalities, thrombophilia allelic polymorphisms and/or consanguinity in Saudi Arabia. BMC Med Genet. 2016;17(Suppl 1):69. doi: https://doi.org/10.1186/s12881-016-0331-1

Chiasakul T, De Jesus E, Tong J, Chen Y, Crow-ther M, Garcia D, et al. Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019;8(19):1-12. doi: https://doi.org/10.1161/JAHA.119.012877

Tzoran I, Papadakis M, Brenner B, Fidalgo Á, Rivas A, Wells PS, et al. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anti-coagulation. Am J Med. 2017;130(4):482.e1-482.e9. doi: https://doi.org/10.1016/j.amjmed.2016.11.016

Colucci G, Tsakiris DA. Thrombophilia Scree¬ning: Universal, Selected, or Neither? Clin Appl Thromb Hemost. 2017;23(8):893-9. doi: https://doi.org/10.1177/1076029616683803

Fishchuk L, Rossokha Z, Pokhylko V, Cher-niavska Y, Popova O, Vershyhora V, et al. SFTPB (rs11130866) and NR3C1 (rs41423247) gene variants as potential clinical biomarkers for personalized treatment strategy selection in patients with severe COVID-19 pneumonia. Respir Investig. 2023;61(1):103-9. doi: https://doi.org/10.1016/j.resinv.2022.10.008

Arachchillage DJ, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M. Thrombophilia testing: A British Society for Haematology guideline. Br J Haematol. 2022;98(3):443-58. doi: https://doi.org/10.1111/bjh.18239

Den Heijer M, Lewington S, Clarke R. Homocys-teine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3(2):292-9. doi: https://doi.org/10.1111/j.1538-7836.2005.01141.x

[Algorithm for providing hospital medical care in case of COVID-19] [Internet]. 2021 [cited 2023 Feb 12]. Ukrainian. Available from: https://moz.gov.ua/uploads/7/35121-algoritm_stac_covid_19.pdf

Fishchuk L, Rossokha Z, Medvedieva N, Vershy-hora V, Sheyko L, Brisevac L, et al. Effect of polymorphic variants of hereditary thrombophilia genes on the risk of early pregnancy loss for married couples. Meta Gene. 2021;29:100902. doi: https://doi.org/10.1016/j.mgene.2021.100902

Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, Lin SR. ERCC2 2251A>C genetic polymo-rphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preli¬minary study. BMC Cancer. 2008;8:50. doi: https://doi.org/10.1186/1471-2407-8-50

Badulescu OV, Sirbu PD, Filip N, Bordeianu G, Cojocaru E, Budacu CC, et al. Hereditary thrombophilia in the era of COVID-19. Healthcare (Basel). 2022;10(6):993. doi: https://doi.org/10.3390/healthcare10060993

Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood. 1995;85(12):3405-11. doi: https://doi.org/10.1182/blood.V85.12.3405.bloodjournal85123405

Msalati A, Bashein A, Ghrew M, Khalil I, Se-daa K, Ali A, et al. Association of venous thromboembo-lism and myocardial infarction with Factor V Leiden and Factor II gene mutations among Libyan patients. Libyan J Med. 2021;16(1):1857525. doi: https://doi.org/10.1080/19932820.2020.1857525

Jusić A, Balić D, Avdić A, Pođanin M, Balić A. The association of factor V G1961A (factor V Leiden), prothrombin G20210A, MTHFR C677T and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss in Bosnian women. Med Glas (Zenica). 2018;15(2):158-63. doi: https://doi.org/10.17392/948-18

Ahmed NA, Adam I, Elzaki SEG, Awooda HA, Hamdan HZ. Factor-V Leiden G1691A and prothrombin G20210A polymorphisms in Sudanese women with preecla¬mpsia, a case-control study. BMC Med Genet. 2019;20(1):2. doi: https://doi.org/10.1186/s12881-018-0737-z

Amara A, Mrad M, Sayeh A, Haggui A, Lahi-deb D, Fekih-Mrissa N, et al. Association of FV G1691A polymorphism but not A4070G with coronary artery di-sease. Clin Appl Thromb Hemost. 2018;24(2):330-7. doi: https://doi.org/10.1177/1076029617744320

AbdelAziz NH, AbdelAzeem HG, Monazea EM, Sherif T. Impact of Thrombophilia on the Risk of Hypoxic-Ischemic Encephalopathy in Term Neonates. Clin Appl Thromb Hemost. 2017;23(3):266-73. doi: https://doi.org/10.1177/1076029615607302

Elmas E, Suvajac N, Jilma B, Weiler H, Borg-grefe M, Dempfle CE. Factor V Leiden mutation enhances fibrin formation and dissolution in vivo in a human endotoxemia model. Blood. 2010;116(5):801-5. doi: https://doi.org/10.1182/blood-2009-03-21321

Rossokha Z, Fishchuk L, Sheyko L, Medve-dieva N, Gorovenko N. Positive effect of betaine-arginine supplement on improved hyperhomocysteinemia treatment in married couples with reproductive disorders. Georgian Med News. 2020;309:22-8.

Tatarskyy P, Kucherenko A, Livshits L. Allelic polymorphism of F2, F5 and MTHFR genes in population of Ukraine. Tsitol Genet. 2010;44(3):3-8. doi: https://doi.org/10.3103/S0095452710030011

Hüls A, Costa ACS, Dierssen M, Baksh RA, Bar-ga¬gna S, Baumer NT, et al. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. eClinicalMedicine. 2021;33:100769. doi: https://doi.org/10.1016/j.eclinm.2021.100769

Clift AK, Coupland CAC, Keogh RH, Hemin-gway H, Hippisley-Cox J. COVID-19 Mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021;174(4):572-6. doi: https://doi.org/10.7326/M20-4986

Illouz T, Biragyn A, Frenkel-Morgenstern M, Weissberg O, Gorohovski A, Merzon E, et al. Specific Susceptibility to COVID-19 in Adults with Down Syndrome. Neuromolecular Med. 2021;(4):561-71. doi: https://doi.org/10.1007/s12017-021-08651-5

Robayo-Amortegui H, Valenzuela-Faccini N, Quecano-Rosas C, et al. Cere¬bral venous thrombosis in a patient with Down syndrome and coronavirus disease 2019: a case report. J Med Case Rep. 2021;15(1):364. doi: https://doi.org/0.1186/s13256-021-02908-0